Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    24
    ...
ATC Name B/G Ingredients Dosage Form Price
M05BX OSSOPAN B Osseine-hydroxyapatite complex - 800mg 800mg Tablet, film coated 1,142,266 L.L
N05AX16 REXULTI B Brexpiprazole - 3mg 3mg Tablet, film coated 13,433,051 L.L
P01AB01 FLAGYL B Metronidazole - 250mg 250mg Tablet, film coated 176,043 L.L
A02BX13 GAVISCON ADVANCE ANISEED FLAVOR B Sodium alginate - 1000mg/10ml, Potassium hydrogen carbonate - 200mg/10ml Suspension 514,692 L.L
A12AX DECALCIT B Vitamin D3 - 500IU, Calcium - 600mg Tablet 912,469 L.L
C07BB07 CONCOR PLUS B Bisoprolol fumarate - 5mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 854,276 L.L
H02AB13 DEFAL B Deflazacort - 6mg 6mg Tablet 415,247 L.L
L01CE01 HYCAMTIN IV B Topotecan HCl - 4mg 4mg Injectable lyophilised powder for solution 52,580,031 L.L
L01XK04 TALZENNA B Talazoparib - 1mg 1mg Capsule 401,512,167 L.L
M01AB05 VOLTFAST B Diclofenac potassium - 50mg 50mg Powder for solution 545,600 L.L
N05AX16 REXULTI B Brexpiprazole - 2mg 2mg Tablet, film coated 13,433,051 L.L
A02BX13 GAVISCON DOUBLE ACTION MINT B Sodium alginate - 250mg, Sodium bicarbonate - 106.5mg, Calcium (carbonate) - 187.5mg Tablet, chewable 456,906 L.L
A12AX DECALCIT B Vitamin D3 - 500IU, Calcium - 600mg Tablet 348,055 L.L
C09DB01 EXFORGE B Amlodipine - 10mg, Valsartan - 160mg Tablet, film coated 1,333,092 L.L
D01BA02 LAMISIL B Terbinafine HCl - 250mg 250mg Tablet, scored 813,025 L.L
G03AD02 ELLAONE B Ulipristal acetate - 30mg 30mg Tablet 2,276,469 L.L
H02AB13 DEFAL B Deflazacort - 30mg 30mg Tablet 635,638 L.L
L01XK04 TALZENNA B Talazoparib - 0.25mg 0.25mg Capsule 133,836,699 L.L
N05AX16 REXULTI B Brexpiprazole - 1mg 1mg Tablet, film coated 13,433,051 L.L
A02BX13 GAVISCON DOUBLE ACTION MINT B Sodium alginate - 500mg/10ml, Sodium bicarbonate - 213mg/10ml, Calcium (carbonate) - 325mg/10ml Suspension 542,912 L.L
G03BA03 TESTOVIRON DEPOT B Testosterone Enantate - 250mg/ml 250mg/ml Injectable solution 456,906 L.L
N05BA01 VALIUM B Diazepam - 5mg 5mg Tablet, scored 200,233 L.L
V03AE03 FOSRENOL B Lanthanum Carbonate - 500mg 500mg Tablet, chewable 18,751,847 L.L
A02BX13 GAVISCON DOUBLE ACTION B Sodium alginate - 500mg, Sodium bicarbonate - 213mg, Calcium (carbonate) - 325mg Suspension 517,379 L.L
A12AX DECALCIT B Vitamin D3 - 750IU, Calcium - 600mg Powder 1,075,074 L.L
G03BB01 PROVIRON B Mesterolone - 25mg 25mg Tablet 391,058 L.L
H03AA01 EUTHYROX B Levothyroxine sodium - 25mcg 25mcg Tablet, scored 256,674 L.L
J01DH02 MERONEM B Meropenem (trihydrate) - 500mg 500mg Injectable powder for solution 10,398,061 L.L
J05AB14 VALCYTE B Valganciclovir (HCl) - 450mg 450mg Tablet, film coated 63,612,039 L.L
V03AE03 FOSRENOL B Lanthanum Carbonate - 750mg 750mg Tablet, chewable 24,138,283 L.L
    ...
    24
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025